Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

People with obesity and prediabetes assigned tirzepatide were more likely to have sustained weight loss than those assigned placebo. Most people on tirzepatide sustained weight loss through 176 weeks.

By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Learn about Zepbound (tirzepatide) storage requirements, including how long you can keep Zepbound in the refrigerator, safe disposal of the drug, and more.

In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone.

Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS.

Zepbound is an FDA-approved injectable weight loss medication. Find out more about Zepbound for weight loss, including how it works and what experts say.

Jenny Mollen opened up about how microdosing GLP1 medication ended up sending her to the emergency room. “I just posted a follow-up to my piece about Tirzepatide and microdosing,” Mollen, 46 ...

A mass rollout of weight loss injections begins across the NHS on Monday, with GPs able to prescribe Mounjaro for the first time. The drug, also known as tirzepatide and manufactured by Lilly, is ...

Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs.

Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working ...